A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy

• Status: Completed
• Trial end date: 2016-04-02
• Target enrollment: 0
• Participant gender: All

Summary

Recent data suggest that areas of fibrosis and hibernating myocardium develop in patients with non ischemic dilated cardiomyopathy. Ranolazine is a new drug, developed to releave symptoms of angina in patients with stable coronary disease that is not suitable for surgical or percutaneous revascularization. It has been shown that in patients with stable coronary disease Ranolazine improves myocardial perfusion as shown with myocardial nuclear imaging. The aim of this trial is to evaluate effects of ranolazine on myocardial perfusion in patients with dilated cardiomyopathy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Medical Centre Ljubljana
• Treatments: Ranolazine

Criteria

Inclusion Criteria:

• established diagnosis of non-ischemic dilated cardiomyopathy

• EF < 35%

• NYHA f.c. II - IV

• Optimal medical management > 6 months

• Age < 75 years and > 18 years

Exclusion Criteria:

• known hypersensitivity to the medication

• age > 75 years or < 18 years

• EF > 35%

• renal insufficiency (GF < 30)

• liver dysfunction (liver tests > 3x the upper normal limit))

• LQT syndrome

• drugs that affect CYP3A4 metabolism (azoles, macrolides, calcineurin inhibitors etc.)

• dementia

• active hemathological or malignant disease